Anti-cardiac Troponin I (phospho) antibody [5E6] (ab8291)

Overview

  • Product nameAnti-cardiac Troponin I (phospho) antibody [5E6]See all Cardiac Troponin I primary antibodies ...
  • Description
    Mouse monoclonal [5E6] to cardiac Troponin I (phospho)
  • SpecificityPhosphorylated form of cardiac troponin I
  • Tested applicationsWB, ELISA more details
  • Species reactivity
    Reacts with: Human, Pig
  • Immunogen

    Phosphorylated form of cardiac troponin I (phosphorylated in the 22nd and 23rd position)

  • General notes


    This antibody detects the phosphorylated form of cardiac troponin

Properties

Applications

Our Abpromise guarantee covers the use of ab8291 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB Use at an assay dependent dilution. Predicted molecular weight: 25 kDa.
ELISA Use at an assay dependent dilution.

Target

  • FunctionTroponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
  • Involvement in diseaseDefects in TNNI3 are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
    Defects in TNNI3 are the cause of cardiomyopathy familial restrictive type 1 (RCM1) [MIM:115210]. RCM1 is an heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
  • Sequence similaritiesBelongs to the troponin I family.
  • Target information above from: UniProt accession P19429 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • cardiac muscle antibody
    • Cardiac troponin I antibody
    • Cardiomyopathy, familial hypertrophic, 7, included antibody
    • CMD1FF antibody
    • CMD2A antibody
    • CMH7 antibody
    • cTnI antibody
    • Familial hypertrophic cardiomyopathy 7 antibody
    • MGC116817 antibody
    • RCM1 antibody
    • Tn1 antibody
    • Tni antibody
    • TNN I3 antibody
    • TNNC 1 antibody
    • TNNC1 antibody
    • TNNI3 antibody
    • TNNI3 antibody
    • TNNI3_HUMAN antibody
    • Troponin I antibody
    • Troponin I cardiac antibody
    • Troponin I cardiac muscle antibody
    • Troponin I cardiac muscle isoform antibody
    • Troponin I type 3 cardiac antibody
    • troponin I, cardiac 3 antibody
    • TroponinI antibody
    • Ttroponin I type 3 (cardiac) antibody
    see all

References for Anti-cardiac Troponin I (phospho) antibody [5E6] (ab8291)

This product has been referenced in:
  • Sarin V  et al. Ca²? sensitization of cardiac myofilament proteins contributes to exercise training-enhanced myocardial function in a porcine model of chronic occlusion. Am J Physiol Heart Circ Physiol 301:H1579-87 (2011). WB ; Pig . Read more (PubMed: 21856915) »
  • Du J  et al. Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI. Am J Physiol Heart Circ Physiol 294:H2604-13 (2008). Read more (PubMed: 18408133) »

See all 2 Publications for this product

Product Wall

Thank you for your email. The ab9936 product is a peptide which can be used to block antibodies ab7829, ab8290 and ab8291. This peptide can be used to block these antibodies irrespective of applications e.g. It is suitable to use with antibodies...

Read More

Thank you for your email. Ab8290 does NOT react with rabbit, and ab8291 has only so far been tested for cross-reactivity with human (not yet tested in rabbit). I unfortunately cannot find another cardiac Troponin I antibody in our catalog that is s...

Read More

The specific epitope has not been mapped but it is situated in the sites of phosphorylation, which are in the 22nd and 23rd position

This antibody is raised against the human protein and species cross-reactivity has not been tested. We recommend 20 ug/ml working concentration for WB.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"